In silico molecular docking and molecular dynamics of Prinsepia utilis phytochemicals as potential inhibitors of phosphodiesterase 4B
Open Access
- 1 November 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Chemical Research
- Vol. 48 (6)
Abstract
Phosphodiesterase 4B is an important enzyme belonging to the phosphodiesterase family, playing a role in regulating the levels of cyclic AMP in cells. Phosphodiesterase 4B degrades cyclic AMP, a crucial signaling molecule involved in numerous biological processes, including inflammation regulation. Recently, the search for potential inhibitors with fewer side effects and high biological activity in valuable medicinal plants has drawn the attention of current scientists. Various in silico methods have been applied to reduce costs and time for experimental studies. In this study, an in silico screening involving a set of 131 natural compounds sourced from Prinsepia utilis species was conducted. These compounds were docked into the active site of the phosphodiesterase 4B protein. As a result, 10 compounds exhibited the most potential inhibitory activity against phosphodiesterase 4B, including 2α- O-trans- p-coumaroyl-3 β,19 α-dihydroxy-urs-12-en-28-oic acid, 2 α- O-cis- p-coumaroyl-3 β,19 α-dihydroxy-urs-12-en-28-oic acid, cyanidin-3- O-rutinoside, delphinidin-3- O-rutinoside, peonidin-3- O-rutinoside, rutin, isorhamnetin-3- O-rutinoside, kaempferol 3- O-α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranoside-7- O- β-D-glucopyranoside, kaempferol 3- O- α-L-rhamnopyranosyl-(1→6) [ α-L-rhamnopyranosyl-(1→2)]- β-D-glucopyranoside, quercetin 3- O-α-L-rhamnopyranosyl-(1→6)- β-D-glucopyranoside were identified through molecular docking simulations. Subsequently, molecular dynamics simulations were performed on these complexes, revealing significant findings regarding their stability. Furthermore, MM–GBSA calculations indicated that the potential compounds had stronger binding free energies than the reference inhibitor. Finally, the selected compounds were subjected to toxicity prediction, showing noteworthy results with large LD50 values and safe toxicity levels. Therefore, these compounds could be potential candidates for further experimental studies as phosphodiesterase 4B inhibitors.Keywords
This publication has 26 references indexed in Scilit:
- Exploring the therapeutic potential of Prinsepia utilis Royle seed oil: A comprehensive study on chemical composition, physicochemical properties, anti-inflammatory, and analgesic activitiesJournal of Ethnopharmacology, 2023
- Prinsepia utilis Royle leaf extract: Ameliorative effects on allergic inflammation and skin lesions in allergic contact dermatitis and polyphenolic profiling through UPLC–MS/MS coupled to chemometric analysisJournal of Ethnopharmacology, 2023
- Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitorHeliyon, 2020
- Blame the signaling: Role of cAMP for the resolution of inflammationPharmacological Research, 2020
- New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studiesMolecular Diversity, 2015
- Discovery of triazines as potent, selective and orally active PDE4 inhibitorsBioorganic & Medicinal Chemistry Letters, 2013
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005
- MMFF VI. MMFF94s option for energy minimization studiesJournal of Computational Chemistry, 1999
- Prinsepiol, a lignan from stems of Prinsepia utilisPhytochemistry, 1982